The COPD Foundation's COPD360Net Initiative Approach to Patient-Centric Drug Development: A Case Study in Using Patient Surveys to Inform New Treatments for Viral Respiratory Infections.

Autor: Tal-Singer R; COPD Foundation, COPD360Net, Washington DC, USA., Miller BE; COPD Foundation, COPD360Net, Washington DC, USA., Rommes JM; COPD Foundation, COPD360Net, Washington DC, USA., Luttmann MA; COPD Foundation, COPD360Net, Washington DC, USA., Demaison C; ENA Respiratory Pty Ltd, Sydney, Australia., Bradley Drummond M; Division of Pulmonary Diseases and Critical Care Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Pasquale CB; COPD Foundation, COPD360Net, Washington DC, USA.

Publikováno v: Journal of patient experience [J Patient Exp] 2023 Jan 26; Vol. 10, pp. 23743735231151554. Date of Electronic Publication: 2023 Jan 26 (Print Publication: 2023).

Pilot Study of a Patient Experience with an ELLIPTA Inhaler Electronic Medication Monitor and Associated Integrated System: A Prospective Observational Study Using the COPD Patient-Powered Research Network.

Autor: Yawn BP; COPD Foundation, Miami, Florida, United States.; Department of Family and Community Health, University of Minnesota, Minneapolis, Minnesota, United States., McCreary GM; COPD Foundation, Miami, Florida, United States., Linnell JA; COPD Foundation, Miami, Florida, United States., Pasquale CB; COPD Foundation, Miami, Florida, United States., Malanga E; COPD Foundation, Miami, Florida, United States., Choate R; COPD Foundation, Miami, Florida, United States.; Department of Epidemiology, College of Public Health University of Kentucky, Lexington, Kentucky, United States., Stempel DA; Respiratory Therapy Area, GlaxoSmithKline plc., Research Triangle Park, North Carolina, United States., Gondalia R; Propeller Health, Madison, Wisconsin, United States., Kaye L; Propeller Health, Madison, Wisconsin, United States., Collison KA; Respiratory Therapy Area, GlaxoSmithKline plc., Research Triangle Park, North Carolina, United States., Wu BS; Respiratory Therapy Area, GlaxoSmithKline plc., Research Triangle Park, North Carolina, United States., Gratie D; Respiratory Therapy Area, GlaxoSmithKline plc., Research Triangle Park, North Carolina, United States., Stanford RH; Respiratory Therapy Area, GlaxoSmithKline plc., Research Triangle Park, North Carolina, United States., Tomlinson R; Respiratory Therapy Area, GlaxoSmithKline plc., Collegeville, Pennsylvania, United States.

Publikováno v: Chronic obstructive pulmonary diseases (Miami, Fla.) [Chronic Obstr Pulm Dis] 2021 Oct 28; Vol. 8 (4), pp. 488-501.

Blood Eosinophil Counts in Clinical Trials for Chronic Obstructive Pulmonary Disease.

Autor: Singh D; Division of Infection, Immunity, and Respiratory Medicine, University of Manchester, Manchester University National Health Service Hospital Trust, Manchester, United Kingdom., Bafadhel M; Respiratory Medicine Unit, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom., Brightling CE; Institute for Lung Health, National Institute for Health Research Leicester Biomedical Research Centre, Department of Respiratory and Infection Sciences, University of Leicester, Leicester, United Kingdom., Sciurba FC; Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania., Curtis JL; Pulmonary and Critical Care Medicine, VA Ann Arbor Healthcare System, Ann Arbor, Michigan.; Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Michigan., Martinez FJ; Pulmonary and Critical Care Medicine, Weill Cornell Medical College, New York, New York., Pasquale CB; COPD Patient-Powered Research Network, COPD Foundation, Washington, DC., Merrill DD; COPD Biomarkers Qualification Consortium, COPD Foundation, Miami, Florida., Metzdorf N; Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany., Petruzzelli S; Global Clinical Development, Chiesi Farmaceutici, Parma, Italy., Tal-Singer R; COPD Biomarkers Qualification Consortium, COPD Foundation, Miami, Florida., Compton C; Global Medical Affairs, Speciality and Primary Care, GlaxoSmithKline, Middlesex, United Kingdom., Rennard S; Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.; University of Nebraska Medical Center, Omaha, Nebraska; and., Martin UJ; Research and Development, AstraZeneca, Gaithersburg, Maryland.

Publikováno v: American journal of respiratory and critical care medicine [Am J Respir Crit Care Med] 2020 Sep 01; Vol. 202 (5), pp. 660-671.

Patient-Reported Consequences of Community-Acquired Pneumonia in Patients with Chronic Obstructive Pulmonary Disease.

Autor: Pasquale CB; Research Department, COPD Foundation, Inc., Washington, D.C., Vietri J; Patient & Health Impact, Pfizer, Inc., Collegeville, Pennsylvania., Choate R; College of Public Health, University of Kentucky Lexington, and Consultant, COPD Foundation, Inc., McDaniel A; Medical Affairs, Pfizer, Inc., Columbia, Missouri., Sato R; Patient & Health Impact, Pfizer, Inc., Collegeville, Pennsylvania., Ford KD; Medical Affairs, Pfizer, Inc., Lexington, Kentucky., Malanga E; Research Department, COPD Foundation, Inc., Washington, D.C., Yawn BP; Research Department, COPD Foundation, Inc., Washington, D.C.

Publikováno v: Chronic obstructive pulmonary diseases (Miami, Fla.) [Chronic Obstr Pulm Dis] 2019 Apr 09; Vol. 6 (2), pp. 132-144. Date of Electronic Publication: 2019 Apr 09.

[Interralation of the 3 basic dental institutions in a community].

Autor: de Di Pasquale CB

Publikováno v: Revista de la Asociacion Odontologica Argentina [Rev Asoc Odontol Argent] 1967 Jun; Vol. 55 (6), pp. 242-7.